Fludrocortisone

Generic Name: Fludrocortisone

Brand Names: Florinef

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₉FO_₅

CAS Number: 127-31-1

Unique Ingredient Identifier: U0476M545B

Background: Fludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary endogenous mineralocorticoid, and is structurally analogous to cortisol, differing only by a fluorine atom at the 9-positio...

Indication: Fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease. It is also indicated for the treatment of salt-losing androgenital syndrome.

Associated Conditions: Otitis Externa, Otitis Media (OM), Primary adrenocortical insufficiency, Secondary adrenocortical insufficiency, Salt-losing Androgenital syndrome

Associated Therapies: -

Clinical Trials

Fludrocortisone's Test in Salt Sensitivity

Phase 4

Conditions: Hypertension

Interventions: Other: Diet cycles
Drug: Fludrocortisone

First Posted Date: 2011-10-18

Last Posted Date: 2011-10-21

Lead Sponsor: Fundação de Amparo à Pesquisa do Estado de São Paulo

Target Recruit Count: 40

Registration Number: NCT01453959

Locations: 🇧🇷
General Hospital of School of Medicine - Universiy of Sao Paulo, Sao Paulo, SP, Brazil

Fludrocortisone for Sudden Hearing Loss

Early Phase 1

Terminated

Conditions: Hearing Loss, Sensorineural

Interventions: Drug: Fludrocortisone

First Posted Date: 2010-08-23

Last Posted Date: 2019-10-18

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 5

Registration Number: NCT01186185

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression

Phase 1

Terminated

Conditions: Renin Angiotensin

Interventions: Drug: Fludrocortisone
Drug: Hydrocortisone
Drug: Placebo of Hydrocortisone
Drug: Placebo of Fludrocortisone

First Posted Date: 2008-05-07

Last Posted Date: 2012-03-02

Lead Sponsor: Rennes University Hospital

Target Recruit Count: 13

Registration Number: NCT00673270

Locations: 🇫🇷
Unité d'Investigation Clinique - Hôpital de Pontchaillou, Rennes, France

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

Not Applicable

Withdrawn

Conditions: Type 1 Diabetes

Interventions: Drug: Fludrocortisone
Drug: Dexamethasone

First Posted Date: 2008-02-06

Last Posted Date: 2014-12-11

Lead Sponsor: Vanderbilt University

Registration Number: NCT00608101

Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock

Phase 3

Completed

Conditions: Septic Shock

Interventions: Drug: recombinant human insulin
Drug: Hydrocortisone
Drug: fludrocortisone

First Posted Date: 2006-05-03

Last Posted Date: 2010-04-06

Lead Sponsor: University of Versailles

Target Recruit Count: 508

Registration Number: NCT00320099

Locations: 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷
Hôpital central, Nancy, France
🇫🇷
Hôpital Avicenne, Bobigny, France

and more 5 locations

Mineralocorticoid Receptor in the Treatment of Severe Depression

Not Applicable

Completed

Conditions: Major Depression

First Posted Date: 2006-02-23

Last Posted Date: 2017-05-30

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 65

Registration Number: NCT00295347

Locations: 🇩🇪
University Hospital Hamburg-Eppendorf, Hamburg, Germany

Clinical Trial for the Prevention of Vasovagal Syncope

Phase 4

Completed

Conditions: Syncope, Vasovagal, Neurally-Mediated

Interventions: Drug: fludrocortisone acetate

First Posted Date: 2005-07-11

Last Posted Date: 2019-10-15

Lead Sponsor: University of Calgary

Target Recruit Count: 213

Registration Number: NCT00118482

Locations: 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦
St. Boniface General Hospital, Winnipeg, Manitoba, Canada
🇨🇦
Queen's University, Kingston, Ontario, Canada

and more 11 locations

Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy

Phase 1

Completed

Conditions: Parkinson's Disease
Multiple System Atrophy
Orthostatic Hypotension

First Posted Date: 2005-02-14

Last Posted Date: 2005-10-20

Lead Sponsor: Royal Brisbane and Women's Hospital

Target Recruit Count: 50

Registration Number: NCT00103597

Locations: 🇦🇺
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Phase 4

Completed

Conditions: Congenital Adrenal Hyperplasia (CAH)

Interventions: Drug: Fludrocortisone
Drug: Hydrocortisone
Drug: Letrozole
Drug: Flutamide

First Posted Date: 1999-11-04

Last Posted Date: 2024-05-10

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 62

Registration Number: NCT00001521

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy